Results 101 to 110 of about 53,092 (237)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort

Alimentary Pharmacology &Therapeutics, EarlyView.
In 1,756,593 young adults, a generalized boosted survival model predicted incident HCC with strong discrimination (1‐year AUROC 0.945; 5‐year 0.825). The 1‐year horizon uniquely targets an imaging‐silent, pre‐diagnosis window, showing routine clinical signals can flag otherwise undetectable risk.
Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim   +7 more
wiley   +1 more source

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care

Alimentary Pharmacology &Therapeutics, EarlyView.
This cross‐sectional study of 84 general practices found 24.3% had At‐Risk MASH defined by FNI > 0.30, and 4.3% had advanced fibrosis defined by FIB‐4 > 2.67. Diabetes and socio‐economic disadvantage were strong predictors of significant liver disease.
Leon A. Adams, Shaoke Lei, Luis Calzadilla‐Bertot, Silja Schrader, Sophie Frear, Chian Zhou, Sarah E. Heywood, Jon Emery   +7 more
wiley   +1 more source

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy [PDF]

Front Pharmacol
Alharbi N, Abdelmageed M, Nader M, Serrya M.   +3 more
europepmc   +2 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Pharmacological activation of NO‐cGMP signalling attenuates metabolic dysfunction‐associated steatohepatitis

British Journal of Pharmacology, EarlyView.
Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth, Malte Roessing, Moritz Lehners, Lisa Dietz, Anja Schmitt, Stephan Hailfinger, Andreas Peter, Leticia Quintanilla‐Martinez, Irene Gonzalez‐Menendez, Ingmar Mederacke, German Ott, Peter Sandner, Matthias Schwab, Robert Feil, Susanne Feil   +14 more
wiley   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

TREM2 in Macrophages Promotes Renal Fibrosis via Activation of β‐Catenin Signalling Pathway in Obstructive Nephropathy

Cell Proliferation, EarlyView.
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) promotes obstructive nephropathy progression by activating the β‐catenin signalling pathway, driving M2 macrophage polarisation, migration and fibrogenic gene expression. targeted inhibition of TREM2 thus represents a promising novel strategy against renal fibrosis.
Jia Wei, Zixia Li, Gengyu Du, Ting Chen, Min Yang, Zhen Yuan, Yidan Zheng, Xiang Yan   +7 more
wiley   +1 more source

Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is associated with an increased risk of cardiovascular disease (CVD) morbidity and mortality. This study aimed to develop the first prediction models for CVD risk in a cohort of patients with MASH.
Joe Hollinghurst, Margarida Augusto, Fotis Tefos, Robert Bauer, Sreelatha Vadapalle, Lise Gehrt Cardél   +5 more
wiley   +1 more source

Role of MicroRNA in Chronic Alcoholic and Non-alcoholic Liver Disease and Pathology

International Journal of Bio-Resource and Stress Management, 2014
MicroRNAs (miRNA) are highly conserve non-coding RNAs which regulate gene expression, different aspect of cell signaling, cellular activity, cell differentiation and development, metabolism, proliferation, programmed cell death, viral and bacterial ...
Biswanath Patra, Vikram Arya
doaj  

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source